查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433660

北美外部藥物 CDMO 市場規模、佔有率和趨勢分析報告：按產品類型、服務類型、贊助商、國家和細分市場進行預測，2024-2030 年

North America Topical Drugs CDMO Market Size, Share & Trends Analysis Report By Product Type (Semi-Solid, Liquid), By Service Type (Contract Development, Contract Manufacturing), By Sponsors, By Country, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

北美外用藥物 CDMO 市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，北美主題CDMO市場規模預計將達到264.5億美元，2024年至2030年複合年成長率為10.7%。

對研發活動的投資不斷增加，以及對多種皮膚病新療法的需求不斷成長，導致局部 CDMO 市場的需求不斷成長。由於易於管理和最小的副作用，消費者對多種局部解決方案的偏好增加也是支持市場成長的因素。

對新穎創新和新產品開發的需求不斷成長預計將改善市場需求，而競爭壓力和價格擔憂則鼓勵公司外包開發新藥和製造。預計這將推動整體市場的成長。此外，CDMO 利用奈米技術等先進技術在分子層面上操縱藥物顆粒，以提高藥物穩定性和生物有效性。此外，微膠囊技術可以保護敏感成分，並實現控制釋放和標靶藥物輸送，從而提高治療效果。這些技術進步正在加速北美市場的成長潛力。

CDMO積極參與與製藥公司的合作和夥伴關係，並已獲得創新藥物開發和多種外用製劑生產的長期契約，預計將推動市場需求。例如，2023 年 1 月，專門從事外用皮膚產品的著名供應商瑞美國CDMO 與 EveryDrop 分配平台的發明者 LiquiGlide 合作。透過此次合作，該公司將利用 LiquiGlide 的創新無毒光滑表面技術來消除液體和固體之間的摩擦，從而消除消費包裝商品的產品廢棄物。

北美專題 CDMO 市場報告亮點：

  • 從產品類型來看，半固態製劑領域佔據市場主導地位，2023年銷售佔有率將超過65.0%。這是因為與口服給藥途徑相比，由於一些副作用，外用藥物具有許多優點，例如易於給藥以及患者更喜歡外用藥物，這正在推動該領域的需求。
  • 按服務類型分類，契約製造預計在預測期內將以顯著的複合年成長率成長。
  • 按贊助商分類，2023 年製藥公司佔最大市場佔有率。製藥公司對創新外用藥物的開發和商業化的開拓投資預計將推動市場收益成長。
  • 由於該地區強大的市場參與企業、政府對優質醫療保健的支持以及對化妝品的高需求等因素，美國在北美局部 CDMO 行業中佔據主導地位。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章 北美專題 CDMO 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 北美外用藥物CDMO市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 價格分析
  • 外用藥物 CDMO 產能展望
  • 按產品類型的北美外用藥物 CDMO 市場前景
  • COVID-19 大流行的影響

第4章 北美外用藥物CDMO市場：產品類型估算及趨勢分析

  • 2023 年及 2030 年產品類型市場佔有率
  • 細分儀表板
  • 北美外用藥品 CDMO 市場的產品展望
  • 2018年至2030年市場規模、預測與趨勢分析

第5章北美外用藥物CDMO市場：服務類型估算及趨勢分析

  • 2023 年及 2030 年服務類型市場佔有率
  • 細分儀表板
  • 按服務類型分類的北美外用藥物 CDMO 市場前景
  • 2018年至2030年市場規模、預測與趨勢分析

第6章 北美外用藥物 CDMO 市場：申辦方估計與趨勢分析

  • 2023年及2030年贊助市場佔有率
  • 細分儀表板
  • 北美外用藥品 CDMO 市場贊助商展望
  • 2018年至2030年市場規模、預測與趨勢分析

第7章 北美外用藥物 CDMO 市場：國家估計與趨勢分析

  • 2023 年及 2030 年國家市場佔有率分析
  • 國家市場儀表板
  • 國家市場概述
  • 2018-2030年市場規模及預測趨勢分析
  • 美國
  • 加拿大

第8章 競爭形勢

  • 公司/競爭對手分類
    • 創新者
    • 市場領導者
    • 新興玩家
    • 2023 年公司市場佔有率分析
  • 公司簡介
    • The Lubrizol Corporation
    • Cambrex Corporation
    • Contract Pharmaceuticals Limited
    • Bora Pharmaceutical CDMO
    • Ascendia Pharmaceuticals
    • Pierre Fabre SA
    • Piramal Pharma Solutions
    • DPT Laboratories, LTD.
    • MedPharm Ltd.
    • Zenvisionpharma
Product Code: GVR-4-68040-188-4

North America Topical Drugs CDMO Market Growth & Trends:

The North America topical drugs CDMO market size is anticipated to reach USD 26.45 billion by 2030, registering a CAGR of 10.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing investment in R&D activities coupled with rising need for novel therapeutics for several dermatological conditions contributes to the growing demand for topical drugs CDMO market. Rising consumer preference for several topical solutions owing to ease of administration and minimized side effects are other factors supporting the growth of the market.

The growing need for novel innovation and new product developments are expected to improve the demand in the market, and competitive pressure & pricing concerns are driving companies to outsource new drug development & manufacturing. This is expected to drive overall market growth. Moreover, CDMOs are leveraging several advanced technologies such as nanotechnology to manipulate drug particles at the molecular level, enhancing drug stability and bioavailability. Moreover, microencapsulation techniques protect sensitive ingredients, allowing for controlled release and targeted drug delivery, amplifying therapeutic outcomes. Such technological advancements are accelerating market growth potential in North America.

CDMOs are actively involved in collaboration & partnerships with pharmaceutical companies to secure long-term contracts for innovative drug development and manufacturing of several topical formulations, which is expected to spur market demand. For instance, in January 2023, Swiss-American CDMO, a prominent provider specializing in topical skin care products, collaborated with LiquiGlide, the inventor of the EveryDrop dispensing platform. Through this collaboration, the company will utilize LiquiGlide's innovative nontoxic slippery surface technology to eliminate friction between liquids & solids and product waste for consumer-packaged goods.

North America Topical Drugs CDMO Market Report Highlights:

  • Based on product type, the semi-solid formulations segment dominated the market with a revenue share of more than 65.0% share in 2023, owing to numerous advantages including ease of administration and patient preference for topical drugs compared to the oral route of administration owing to several adverse effects, which is expected to drive segment demand
  • Based on service type, the contract manufacturing segment is expected to grow at the substantial CAGR over the forecast period
  • Based on sponsors, the pharmaceutical companies segment held the largest market share in 2023. Growing R&D investments by several pharmaceutical companies to develop and commercialize innovative topical drugs is anticipated to boost market revenue growth
  • The U.S. dominated the North America topical drugs CDMO industry owing to factors such as strong presence of market participants in the region, government support for quality healthcare and high demand for cosmetic products

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Details of primary research
    • 1.5.1. Data for primary interviews in the U.S.
    • 1.5.2. Data for primary interviews in Canada
  • 1.6. Information or Data Analysis
    • 1.6.1. Data analysis models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity flow analysis (Model 1)
    • 1.8.2. Approach 1: Commodity flow approach
    • 1.8.3. Parent Market Analysis (Model 2)
    • 1.8.4. Approach 2: Parent Market Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Primary Sources
  • 1.11. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Topical Drugs CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Technological advancements & growing R&D investments
      • 3.2.1.2. Rising demand for topical medications
      • 3.2.1.3. Expansion of manufacturing capacities and partnerships
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance with strict regulatory requirements
      • 3.2.2.2. Limited efficacy in certain conditions limits adoption of topical products
  • 3.3. North America Topical Drugs CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
  • 3.4. Pricing Analysis
  • 3.5. Topical Drugs CDMO Capacity Outlook
    • 3.5.1. CDMO Manufacturing Container Capacity
    • 3.5.2. Topical Drugs Container Capacity By Product Type
  • 3.6. North America Topical Drugs CDMO Market Outlook By Product Category
    • 3.6.1. North America Topical Drugs CDMO Market Share, By Product Category, 2023 (%)
    • 3.6.2. Prescription Drugs
      • 3.6.2.1. Segment Overview
      • 3.6.2.2. Major Prescription Drugs, By Product Type
    • 3.6.3. Generic Drugs
      • 3.6.3.1. Segment Overview
      • 3.6.3.2. Major Generic Drugs, By Product Type
    • 3.6.4. Over-the-counter (OTC) Drugs
      • 3.6.4.1. Segment Overview
      • 3.6.4.2. Major OTC Drugs, By Product Type
  • 3.7. Impact of COVID-19 Pandemic

Chapter 4. North America Topical Drugs CDMO Market: Product Type Estimates & Trend Analysis

  • 4.1. Product Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. North America Topical Drugs CDMO Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Semi-solid Formulations
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Creams
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Ointments
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Lotions
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Others
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Liquid Formulations
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Suspensions
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Solutions
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Solid Formulations
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Transdermal Products
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. North America Topical Drugs CDMO Market: Service Type Estimates & Trend Analysis

  • 5.1. Service Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. North America Topical Drugs CDMO Market by Service Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Contract Development
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Formulation Development
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Analytical Testing
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.4. Stability Testing
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.5. Others
      • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Contract Manufacturing
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Clinical
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. Commercial
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. North America Topical Drugs CDMO Market: Sponsors Estimates & Trend Analysis

  • 6.1. Sponsors Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. North America Topical Drugs CDMO Market by Sponsors Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Pharmaceutical Companies
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Biopharmaceutical Companies
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. North America Topical Drugs CDMO Market: Country Estimates & Trend Analysis

  • 7.1. Country Market Share Analysis, 2023 & 2030
  • 7.2. Country Market Dashboard
  • 7.3. Country Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. U.S.
    • 7.5.1. Key country dynamics
    • 7.5.2. Regulatory framework
    • 7.5.3. Competitive scenario
    • 7.5.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Canada
    • 7.6.1. Key country dynamics
    • 7.6.2. Regulatory framework
    • 7.6.3. Competitive scenario
    • 7.6.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2023
  • 8.2. Company Profiles
    • 8.2.1. The Lubrizol Corporation
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product/service benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Cambrex Corporation
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product/service benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Contract Pharmaceuticals Limited
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product/service benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Bora Pharmaceutical CDMO
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product/service benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Ascendia Pharmaceuticals
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product/service benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Pierre Fabre S.A.
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product/service benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Piramal Pharma Solutions
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product/service benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. DPT Laboratories, LTD.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product/service benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. MedPharm Ltd.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product/service benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Zenvisionpharma
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product/service benchmarking
      • 8.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Topical Drugs CDMO: Market Revenue Estimates and Forecast, 2018 - 2030 (USD Billion)
  • Table 4 Global Topical Drugs: Market Revenue Estimates and Forecast, 2018 - 2030 (USD Billion)
  • Table 5 Development Stages Baseline Model Parameter Estimates, By Topical Drugs
  • Table 6 Global Topical Drugs CDMO Manufacturing Container Capacity/Batch
  • Table 7 Global Topical Drugs Capacity, by Product Type (per unit)
  • Table 8 Global Topical Drugs Capacity, by Container Type (per unit)
  • Table 9 North America Topical Drugs CDMO Market Share, By Product Category, 2023 (%)
  • Table 10 List of Major Prescription Drugs, by Product Type (2022)
  • Table 11 List of Major Generic Drugs, by Product Type (2022)
  • Table 12 List of major OTC Drugs, by Product Type (2022)
  • Table 13 North America Topical Drugs CDMO market revenue estimates and forecast, by Product type, 2018 - 2030 (USD Million)
  • Table 14 North America Topical Drugs CDMO market revenue estimates and forecast, by Semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 15 North America Topical Drugs CDMO market revenue estimates and forecast, by Liquid formulations drugs, 2018 - 2030 (USD Million)
  • Table 16 North America Topical Drugs CDMO market revenue estimates and forecast, by service type, 2018 - 2030 (USD Million)
  • Table 17 North America Topical Drugs CDMO market revenue estimates and forecast, by contract development, 2018 - 2030 (USD Million)
  • Table 18 North America Topical Drugs CDMO market revenue estimates and forecast, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 19 North America Topical Drugs CDMO market revenue estimates and forecast, by sponsors, 2018 - 2030 (USD Million)
  • Table 20 North America Topical Drugs CDMO market revenue estimates and forecast, by country, 2018 - 2030 (USD Million)
  • Table 21 Company profiles: Company overview
  • Table 22 Company profiles: Financial performance
  • Table 23 Company profiles: Service benchmarking
  • Table 24 Key Company initiating service launches/upgrades
  • Table 25 Key companies initiating mergers/acquisitions/joint ventures
  • Table 26 Key companies initiating partnerships
  • Table 27 Key companies initiating expansion
  • Table 28 Key companies initiating others 

List of Figures

  • Fig. 1 North America topical drugs CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Global topical drugs CDMO market outlook, 2023 (USD Billion)
  • Fig. 13 Global topical drugs market outlook, 2023 (USD Billion)
  • Fig. 14 North America topical drugs CDMO market dynamics
  • Fig. 15 Porter's Five Forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 North America Topical Drugs CDMO market: Product Type outlook and key takeaways
  • Fig. 18 North America Topical Drugs CDMO market: Product Type movement analysis
  • Fig. 19 Semi-solid formulations market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Creams market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Ointments market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Lotions market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Liquid formulations market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Suspensions market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Solutions market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Solid formulations market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Transdermal products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 North America Topical Drugs CDMO market: Service type outlook and key takeaways
  • Fig. 30 North America Topical Drugs CDMO market: Service type movement analysis
  • Fig. 31 Contract development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Formulation development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Analytical testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Stability testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Clinical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Commercial market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 North America Topical Drugs CDMO market: sponsors outlook and key takeaways
  • Fig. 40 North America Topical Drugs CDMO market: sponsors movement analysis
  • Fig. 41 Pharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Biopharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 North America Topical Drugs CDMO market revenue, by country, 2023 & 2030 (USD Million)
  • Fig. 45 Regional outlook, 2023 & 2030
  • Fig. 46 Regional Market Share Analysis, 2023 & 2030
  • Fig. 47 North America Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 U.S. Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Canada Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Market participant categorization
  • Fig. 53 Market participant categorization
  • Fig. 54 Heat map analysis